Lon Cardon's most recent trade in Mirum Pharmaceuticals Inc was a trade of 6,268 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 6,268 | 6,268 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 5,703 | 0 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 5,703 | 5,703 (0%) | 0% | - | Common Stock | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 3,977 | 3,977 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 8,779 | 8,779 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,703 | 5,703 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 7,083 | 7,083 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Lon Cardon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2021 | 14,000 | 14,000 | - | - | Stock Option (right to buy) |